이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Upexi 과거 수익 실적

이 회사의 최신 수익 보고서는 아직 처리 중입니다.

과거 기준 확인 0/6

Upexi의 수입은 연평균 -56.8%의 비율로 감소해 온 반면, Personal Products 산업은 수입이 연평균 14.8%의 비율로 증가했습니다. 매출은 연평균 65.8%의 비율로 증가해 왔습니다.

주요 정보

-56.8%

수익 성장률

-37.0%

EPS 성장률

Personal Products 산업 성장	20.9%
매출 성장률	65.8%
자기자본 수익률	-79.5%
순이익	-21.7%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

수익 및 비용 분석

Upexi 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NasdaqCM:UPXI 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용
31 Dec 23	92	-20	35
30 Sep 23	97	-14	37
30 Jun 23	81	-15	36
31 Mar 23	72	-3	34
31 Dec 22	52	-1	28
30 Sep 22	30	-7	24
30 Jun 22	23	-6	20
31 Mar 22	24	-1	18
31 Dec 21	26	0	15
30 Sep 21	25	3	11
30 Jun 21	24	3	9
31 Mar 21	16	0	7
31 Dec 20	11	-3	8
30 Sep 20	9	-5	8
30 Jun 20	7	-5	7
30 Jun 19	2	-1	2

양질의 수익: UPXI 은(는) 현재 수익성이 없습니다.

이익 마진 증가: UPXI 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: UPXI 은(는) 수익성이 없으며 지난 5년 동안 연간 56.8% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 UPXI 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: UPXI 은(는) 수익성이 없어 지난 해 수익 성장을 Personal Products 업계( 6.9% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: UPXI 현재 수익성이 없기 때문에 마이너스 자본 수익률( -79.48% )을 갖습니다.

Upexi 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Recent updates

Upexi Provides Update on Filing Form 10Q for March 31, 2024

Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024

MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc., Annual General Meeting, Jun 10, 2024

New major risk - Market cap size

Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Consensus revenue estimates fall by 17%

Consensus revenue estimates fall by 17%

This Analyst Just Downgraded Their Upexi, Inc. (NASDAQ:UPXI) EPS Forecasts

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Upexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023

Upexi, Inc. announced delayed 10-Q filing

Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog Supplements

Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.

Upexi, Inc. (NASDAQ:UPXI) Doing What It Can To Lift Shares

Upexi, Inc., Annual General Meeting, Jun 26, 2023

Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Upexi, Inc. announced delayed 10-Q filing

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)

CEO, President & Chairman of the Board recently bought US$73k worth of stock

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.

Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.

Upexi, Inc. Files Patent for its Single Click-to-optin Technology

Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)

Upexi, Inc. Appoints Anthony Bazan as Chief Operating Officer

Investor sentiment deteriorated over the past week

Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.

Investor sentiment improved over the past week

Grove CEO provides company update on sales and beyond

Investor sentiment improved over the past week

Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)

High number of new and inexperienced directors

Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.

Grove, Inc., Annual General Meeting, May 24, 2022

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)

Investor sentiment improved over the past week

Why Grove's (NASDAQ:GRVI) Earnings Are Weaker Than They Seem

Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)

Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.

Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.

Grove: An Underrated CBD Player

Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation.

Grove, Inc. has completed an IPO in the amount of $11 million.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기